- Home
- TWN vs CRDF Comparison
TWN vs CRDF Comparison
Compare TWN & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWN
- CRDF
- Stock Information
- Founded
- TWN 1986
- CRDF 1999
- Country
- TWN Hong Kong
- CRDF United States
- Employees
- TWN N/A
- CRDF N/A
- Industry
- TWN Trusts Except Educational Religious and Charitable
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TWN Finance
- CRDF Health Care
- Exchange
- TWN Nasdaq
- CRDF Nasdaq
- Market Cap
- TWN 278.0M
- CRDF 288.7M
- IPO Year
- TWN N/A
- CRDF N/A
- Fundamental
- Price
- TWN $36.17
- CRDF $3.86
- Analyst Decision
- TWN
- CRDF Strong Buy
- Analyst Count
- TWN 0
- CRDF 3
- Target Price
- TWN N/A
- CRDF $10.33
- AVG Volume (30 Days)
- TWN 20.1K
- CRDF 1.1M
- Earning Date
- TWN 01-01-0001
- CRDF 05-01-2025
- Dividend Yield
- TWN 1.10%
- CRDF N/A
- EPS Growth
- TWN N/A
- CRDF N/A
- EPS
- TWN N/A
- CRDF N/A
- Revenue
- TWN N/A
- CRDF $683,000.00
- Revenue This Year
- TWN N/A
- CRDF N/A
- Revenue Next Year
- TWN N/A
- CRDF N/A
- P/E Ratio
- TWN N/A
- CRDF N/A
- Revenue Growth
- TWN N/A
- CRDF 39.96
- 52 Week Low
- TWN $25.22
- CRDF $2.01
- 52 Week High
- TWN $41.51
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- TWN 34.23
- CRDF 45.43
- Support Level
- TWN $35.59
- CRDF $3.62
- Resistance Level
- TWN $37.35
- CRDF $4.31
- Average True Range (ATR)
- TWN 1.08
- CRDF 0.43
- MACD
- TWN -0.14
- CRDF -0.08
- Stochastic Oscillator
- TWN 15.22
- CRDF 17.15
About TWN Taiwan Fund Inc. (The)
Taiwan Fund Inc is a diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment predominantly in equity securities listed in Taiwan stock exchange and the Republic of China. In selecting the companies for investments fund's portfolio managers will consider overall growth prospects, competitive position in the respective industry technology, research, and development, productivity, profit margins, return on investment, capital resources, government regulation, management and other factors.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").